The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

Strong Market Growth

• The POC coagulation testing devices market has seen significant growth, expanding from $1.93 billion in 2023 to $2.12 billion in 2024, representing a 9.6% CAGR.
• This growth is driven by an increase in chronic and infectious diseases, an aging population, and advancements in portable diagnostic technologies.

Future Market Projections

• The market is expected to reach $3.07 billion by 2028 with a 9.8% CAGR.
• The future expansion will be fueled by the rising demand for rapid and accurate disease diagnosis, the growth of telemedicine, and advancements in diagnostic testing technologies.

View More On The Point-of-Care (POC) Coagulation Testing Devices Market Report 2024 – https://www.thebusinessresearchcompany.com/report/point-of-care-poc-coagulation-testing-devices-global-market-report

Key Growth Drivers

• Prevalence of Blood Clotting Disorders: Increasing cases of hemophilia, von Willebrand disease, and other clotting disorders are pushing the demand for POC coagulation devices.
• Lifestyle Factors: Smoking, excessive alcohol consumption, and sedentary lifestyles contribute to the rise in blood clotting disorders, highlighting the need for quick diagnostic tools.
• Technological Advancements: The integration of next-generation sequencing (NGS), AI, and microfluidic technologies into diagnostic devices is transforming the POC testing landscape.

The Role of Major Industry Players

• Companies like Roche Diagnostics, Thermo Fisher Scientific, and Abbott Laboratories are at the forefront of innovation in the POC coagulation testing market.
• Cipla Limited has developed Cippoint, an immunofluorescence-based analyzer, which provides rapid results in 3 to 15 minutes, enhancing diagnostic accuracy and patient care.

Strategic Mergers and Acquisitions

• LumiraDx’s merger with CA Healthcare Acquisition Corp. for $3 billion in 2021 underscores the industry’s focus on expanding diagnostic capabilities through strategic partnerships.
• This merger allows LumiraDx to leverage its innovative platform, which includes over 30 assays covering various health conditions, to offer advanced coagulation testing solutions.

Technological Innovations Leading the Way

• Immunofluorescence-Based Quantitative Analysis: This technology is revolutionizing coagulation testing by enabling faster, more accurate diagnosis and management of blood clotting disorders.
• Artificial Intelligence (AI) and Data Analytics: The use of AI in diagnostics is enhancing the precision and speed of coagulation testing, leading to better patient outcomes.

Market Segmentation

• Product Types: The market includes coagulation monitors, consumables, and analyzers.
• Technology: It spans optical, mechanical, and electrochemical technologies.
• Methods: Prothrombin time and international normalized ratio (INR) testing are common, alongside viscoelastic coagulation monitoring and other methods.
• Applications: These devices are used in blood glucose testing, infectious diseases testing, cardiac markers testing, and coagulation testing.
• End-Users: The primary users are hospitals, diagnostic laboratories, and clinics.

Conclusion: A Rapidly Evolving Market

The POC coagulation testing devices market is poised for continued growth, driven by rising demand for rapid diagnostics, technological advancements, and a growing emphasis on preventive healthcare. With key players pushing the boundaries of innovation, the market is set to play a crucial role in the future of healthcare diagnostics.

Request A Sample Of The Global Point-of-Care (POC) Coagulation Testing Devices Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=15636&type=smp